日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Artificial Intelligence-Based Digital Histologic Classifier for Prostate Cancer Risk Stratification: Independent Blinded Validation in Patients Treated With Radical Prostatectomy

基于人工智能的前列腺癌风险分层数字组织学分类器:根治性前列腺切除术患者的独立盲法验证

Fay, Magdalena; Liao, Ross S; Lone, Zaeem M; Reddy, Chandana A; Muhammad, Hassan; Xie, Chensu; Jain, Parag; Huang, Wei; Basu, Hirak S; Nair, Sujit S; Chakravarty, Dimple; Williamson, Sean R; Gupta, Shilpa; Weight, Christopher; Roy, Rajat; Wilding, George; Tewari, Ashutosh K; Klein, Eric A; Mian, Omar Y

Mediator kinase inhibition reverses castration resistance of advanced prostate cancer

介质激酶抑制剂可逆转晚期前列腺癌的去势抵抗性

Li, Jing; Hilimire, Thomas A; Liu, Yueying; Wang, Lili; Liang, Jiaxin; Gyorffy, Balazs; Sikirzhytski, Vitali; Ji, Hao; Zhang, Li; Cheng, Chen; Ding, Xiaokai; Kerr, Kendall R; Dowling, Charles E; Chumanevich, Alexander A; Mack, Zachary T; Schools, Gary P; Lim, Chang-Uk; Ellis, Leigh; Zi, Xiaolin; Porter, Donald C; Broude, Eugenia V; McInnes, Campbell; Wilding, George; Lilly, Michael B; Roninson, Igor B; Chen, Mengqian

Predicting Response of Triple-Negative Breast Cancer to Neoadjuvant Chemotherapy Using a Deep Convolutional Neural Network-Based Artificial Intelligence Tool

利用基于深度卷积神经网络的人工智能工具预测三阴性乳腺癌对新辅助化疗的反应

Krishnamurthy, Savitri; Jain, Parag; Tripathy, Debu; Basset, Roland; Randhawa, Ramandeep; Muhammad, Hassan; Huang, Wei; Yang, Hua; Kummar, Shivaani; Wilding, George; Roy, Rajat

Prostate cancer cells survive anti-androgen and mitochondrial metabolic inhibitors by modulating glycolysis and mitochondrial metabolic activities

前列腺癌细胞通过调节糖酵解和线粒体代谢活动来抵抗抗雄激素和线粒体代谢抑制剂的作用。

Basu, Hirak S; Wilganowski, Nathaniel; Robertson, Samantha; Reuben, James M; Cohen, Evan N; Zurita, Amado; Ramachandran, Sumankalai; Xiao, Lian-Chun; Titus, Mark; Wilding, George

Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma: ECOG-ACRIN Cancer Research Group (E1898) Trial

转移性激素难治性前列腺癌每周紫杉醇联合雌莫司汀治疗的II期研究:ECOG-ACRIN癌症研究组(E1898)试验

Wong, Yu-Ning; Manola, Judith; Hudes, Gary R; Roth, Bruce J; Moul, Judd W; Barsevick, Andrea M; Scher, Richard M; Volk, Michael J; Vaughn, David J; Williams, Stephen D; Fisch, Michael J; Cella, David; Carducci, Michael A; Wilding, George

A Festschrift in Honor of Edward M. Messing, MD, FACS

纪念爱德华·梅辛 (Edward M. Messing) 医学博士、FACS 的纪念文集

Joseph, Jean V; Brasacchio, Ralph; Fung, Chunkit; Reeder, Jay; Bylund, Kevin; Sahasrabudhe, Deepak; Yeh, Shu Yuan; Ghazi, Ahmed; Fultz, Patrick; Rubens, Deborah; Wu, Guan; Singer, Eric; Schwarz, Edward; Mohile, Supriya; Mohler, James; Theodorescu, Dan; Lee, Yi Fen; Okunieff, Paul; McConkey, David; Rashid, Hani; Chang, Chawnshang; Fradet, Yves; Guru, Khurshid; Kukreja, Janet; Sufrin, Gerald; Lotan, Yair; Bailey, Howard; Noyes, Katia; Schwartz, Seymour; Rideout, Kathy; Bratslavsky, Gennady; Campbell, Steven C; Derweesh, Ithaar; Abrahamsson, Per-Anders; Soloway, Mark; Gomella, Leonard; Golijanin, Dragan; Svatek, Robert; Frye, Thomas; Lerner, Seth; Palapattu, Ganesh; Wilding, George; Droller, Michael; Trump, Donald

Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement

临床试验的特征和受试者招募障碍:MD安德森癌症中心30余年的经验,为试验改进奠定了历史基础

Tang, Chad; Sherman, Steven I; Price, Mellanie; Weng, Jun; Davis, Suzanne E; Hong, David S; Yao, James C; Buzdar, Aman; Wilding, George; Lee, J Jack

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

去势抵抗性前列腺癌的试验设计和目标:前列腺癌临床试验工作组3的最新建议

Scher, Howard I; Morris, Michael J; Stadler, Walter M; Higano, Celestia; Basch, Ethan; Fizazi, Karim; Antonarakis, Emmanuel S; Beer, Tomasz M; Carducci, Michael A; Chi, Kim N; Corn, Paul G; de Bono, Johann S; Dreicer, Robert; George, Daniel J; Heath, Elisabeth I; Hussain, Maha; Kelly, Wm Kevin; Liu, Glenn; Logothetis, Christopher; Nanus, David; Stein, Mark N; Rathkopf, Dana E; Slovin, Susan F; Ryan, Charles J; Sartor, Oliver; Small, Eric J; Smith, Matthew Raymond; Sternberg, Cora N; Taplin, Mary-Ellen; Wilding, George; Nelson, Peter S; Schwartz, Lawrence H; Halabi, Susan; Kantoff, Philip W; Armstrong, Andrew J

Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib

肾功能损害对阿昔替尼药代动力学和安全性的影响

Chen, Ying; Rini, Brian I; Motzer, Robert J; Dutcher, Janice P; Rixe, Olivier; Wilding, George; Stadler, Walter M; Tarazi, Jamal; Garrett, May; Pithavala, Yazdi K

A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer

一项针对难治性实体瘤和KRAS突变型结直肠癌的selumetinib(AZD6244/ARRY-142866,一种MEK1/2抑制剂)联合西妥昔单抗的I期研究

Deming, Dustin A; Cavalcante, Ludmila L; Lubner, Sam J; Mulkerin, Daniel L; LoConte, Noelle K; Eickhoff, Jens C; Kolesar, Jill M; Fioravanti, Suzanne; Greten, Tim F; Compton, Kathryn; Doyle, Austin G; Wilding, George; Duffy, Austin; Liu, Glenn